Clinical Trials Browser

Phase 2 × INDUSTRY × Mesothelioma × Clear all

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02004028 2024-02-20

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Phase 2 Terminated

35 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Adenoma, Mesothelioma, Neoplasms, Mesothelial

NCT03926143 2023-08-04

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Phase 2 Terminated

9 enrolled 10 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02860286 2021-04-09

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Phase 2 Completed

74 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02610140 2020-11-04

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Phase 2 Completed

248 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02187783 2019-07-18

SIGNATURE

Phase 2 Completed

106 enrolled 16 charts

BreastGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmThoracic

Breast Neoplasms, Leukemia, Lymphoma, Mesothelioma, Neoplasms, Ovarian Neoplasms, Hematologic Neoplasms

NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Phase 2 Completed

185 enrolled

BreastDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT00597116 2016-10-10